MCT4 inhibitors (Ryvu Therapeutics/Merck Healthcare/EMD Serono/Intana Bioscience)

N/A

Report date: 2025/03/20 15:42:51
NME

Base Information

Drug NameMCT4 inhibitors (Ryvu Therapeutics/Merck Healthcare/EMD Serono/Intana Bioscience)
Drug Alias Namemonocarboxylate transporter 4 inhibitors (Ryvu Therapeutics/Merck Healthcare/EMD Serono/Intana Bioscience)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMonocarboxylate transporter 4 inhibitors
TargetsMonocarboxylate transporter 4
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPolandGermany
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRyvu Therapeutics Sa
China Registration ClassN/A

Develop Information

Active CompaniesRyvu Therapeutics SaEMD Serono Research CenterBioScience GmbH +[4] 
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A